Autopsy report · NCT03850028

Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients

“Closed prematurely because the accrual was not achieved”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

University Medical Center Groningen

Sponsor type

University, hospital or other

Conditions

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Interventions

89Zr-atezolizumab PET scans

Participants

0

Sites

2

Countries

Netherlands

Trials that died the same way

• Nipple Secretion Samples in Detecting Breast Cancer in Patients and Healthy Participants Undergoing Breast Cancer Screening, Breast Diagnostic Studies, or Treatment for Benign Breast Disease
  “Closed due to low accrual” (81% match in meaning)
• Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL
  “Closed early due to poor accrual.” (81% match in meaning)
• Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
  “Closed early due to slow accrual” (80% match in meaning)
• Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma
  “Closed early due to low accrual.” (80% match in meaning)
• S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium
  “Permanently Closed Due to Poor Accrual” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.